According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Separately, Rodman & Renshaw set a $3.30 price target on shares of OpGen and gave the stock a buy rating in a research note on Wednesday, August 10th.
Shares of OpGen (NASDAQ:OPGN) traded down 3.45% during midday trading on Wednesday, hitting $1.40. 13,214 shares of the stock were exchanged. OpGen has a 12-month low of $1.02 and a 12-month high of $4.65. The firm’s market cap is $30.33 million. The stock’s 50 day moving average is $1.64 and its 200 day moving average is $1.61.
OpGen (NASDAQ:OPGN) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.09. On average, equities research analysts forecast that OpGen will post ($1.17) earnings per share for the current fiscal year.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.